• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于网络的方法鉴定胰腺导管腺癌亚型特异性主调控因子

A Network-Based Approach for Identification of Subtype-Specific Master Regulators in Pancreatic Ductal Adenocarcinoma.

机构信息

Department of Biomedical Sciences, City University of Hong Kong, Hong Kong SAR, China.

Shenzhen Research Institute, City University of Hong Kong, Shenzhen 518057, China.

出版信息

Genes (Basel). 2020 Feb 1;11(2):155. doi: 10.3390/genes11020155.

DOI:10.3390/genes11020155
PMID:32024063
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7074188/
Abstract

Pancreatic ductal adenocarcinoma (PDAC), the predominant subtype of pancreatic cancer, has been reported with equal mortality and incidence for decades. The lethality of PDAC is largely due to its late presentation, when surgical resection is no longer an option. Similar to other major malignancies, it is now clear that PDAC is not a single disease, posing a great challenge to precise selection of patients for optimized adjuvant therapy. A representative study found that PDAC comprises four distinct molecular subtypes: squamous, pancreatic progenitor, immunogenic, and aberrantly differentiated endocrine exocrine (ADEX). However, little is known about the molecular mechanisms underlying specific PDAC subtypes, hampering the design of novel targeted agents. In this study we performed network inference that integrates miRNA expression and gene expression profiles to dissect the miRNA regulatory mechanism specific to the most aggressive squamous subtype of PDAC. Master regulatory analysis revealed that the particular subtype of PDAC is predominantly influenced by miR-29c and miR-192. Further integrative analysis found miR-29c target genes LOXL2, ADAM12 and SERPINH1, which all showed strong association with prognosis. Furthermore, we have preliminarily revealed that the PDAC cell lines with high expression of these miRNA target genes showed significantly lower sensitivities to multiple anti-tumor drugs. Together, our integrative analysis elucidated the squamous subtype-specific regulatory mechanism, and identified master regulatory miRNAs and their downstream genes, which are potential prognostic and predictive biomarkers.

摘要

胰腺导管腺癌 (PDAC) 是胰腺癌的主要亚型,几十年来其死亡率和发病率一直持平。PDAC 的致命性在很大程度上是由于其晚期表现,此时手术切除已不再是一种选择。与其他主要恶性肿瘤类似,现在很明显 PDAC 不是一种单一的疾病,这对优化辅助治疗患者的精确选择构成了巨大挑战。一项代表性研究发现,PDAC 包括四个不同的分子亚型:鳞状细胞、胰腺祖细胞、免疫原性和异常分化的内分泌外分泌 (ADEX)。然而,对于特定 PDAC 亚型的分子机制知之甚少,这阻碍了新型靶向药物的设计。在这项研究中,我们进行了网络推断,该推断整合了 miRNA 表达和基因表达谱,以剖析 PDAC 中最具侵袭性的鳞状亚型特有的 miRNA 调控机制。主调控分析表明,PDAC 的特定亚型主要受 miR-29c 和 miR-192 的影响。进一步的综合分析发现 miR-29c 的靶基因 LOXL2、ADAM12 和 SERPINH1,它们都与预后有很强的关联。此外,我们还初步揭示了这些 miRNA 靶基因高表达的 PDAC 细胞系对多种抗肿瘤药物的敏感性明显降低。总之,我们的综合分析阐明了鳞状亚型特有的调控机制,并确定了主调控 miRNA 及其下游基因,它们是潜在的预后和预测生物标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e689/7074188/5bcfc34dd4dc/genes-11-00155-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e689/7074188/82a216c5bba3/genes-11-00155-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e689/7074188/918a15c89840/genes-11-00155-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e689/7074188/c55e98115978/genes-11-00155-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e689/7074188/9fbef96c22f9/genes-11-00155-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e689/7074188/7507c3693a7e/genes-11-00155-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e689/7074188/97e05e81bdca/genes-11-00155-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e689/7074188/5bcfc34dd4dc/genes-11-00155-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e689/7074188/82a216c5bba3/genes-11-00155-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e689/7074188/918a15c89840/genes-11-00155-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e689/7074188/c55e98115978/genes-11-00155-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e689/7074188/9fbef96c22f9/genes-11-00155-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e689/7074188/7507c3693a7e/genes-11-00155-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e689/7074188/97e05e81bdca/genes-11-00155-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e689/7074188/5bcfc34dd4dc/genes-11-00155-g007.jpg

相似文献

1
A Network-Based Approach for Identification of Subtype-Specific Master Regulators in Pancreatic Ductal Adenocarcinoma.基于网络的方法鉴定胰腺导管腺癌亚型特异性主调控因子
Genes (Basel). 2020 Feb 1;11(2):155. doi: 10.3390/genes11020155.
2
Identification of novel genes associated with a poor prognosis in pancreatic ductal adenocarcinoma via a bioinformatics analysis.通过生物信息学分析鉴定与胰腺导管腺癌预后不良相关的新基因。
Biosci Rep. 2019 Aug 2;39(8). doi: 10.1042/BSR20190625. Print 2019 Aug 30.
3
SCNrank: spectral clustering for network-based ranking to reveal potential drug targets and its application in pancreatic ductal adenocarcinoma.SCNrank:基于网络的排序的谱聚类揭示潜在的药物靶点及其在胰腺导管腺癌中的应用。
BMC Med Genomics. 2020 Apr 3;13(Suppl 5):50. doi: 10.1186/s12920-020-0681-6.
4
Identification of candidate miRNA biomarkers for pancreatic ductal adenocarcinoma by weighted gene co-expression network analysis.通过加权基因共表达网络分析鉴定胰腺导管腺癌的候选 miRNA 生物标志物
Cell Oncol (Dordr). 2017 Apr;40(2):181-192. doi: 10.1007/s13402-017-0315-y. Epub 2017 Feb 15.
5
Gene expression profiling of 1200 pancreatic ductal adenocarcinoma reveals novel subtypes.对 1200 例胰腺导管腺癌的基因表达谱分析揭示了新的亚型。
BMC Cancer. 2018 May 29;18(1):603. doi: 10.1186/s12885-018-4546-8.
6
Potential four‑miRNA signature associated with T stage and prognosis of patients with pancreatic ductal adenocarcinoma identified by co‑expression analysis.通过共表达分析鉴定与胰腺导管腺癌 T 分期和预后相关的潜在四 miRNA 特征。
Mol Med Rep. 2019 Jan;19(1):441-451. doi: 10.3892/mmr.2018.9663. Epub 2018 Nov 19.
7
Prognostic relevance of molecular subtypes and master regulators in pancreatic ductal adenocarcinoma.胰腺导管腺癌中分子亚型和主调控因子的预后相关性
BMC Cancer. 2016 Aug 12;16:632. doi: 10.1186/s12885-016-2540-6.
8
Analysis of Blood Plasma MicroRNAs to Enable Identification of Patients with Pancreatic Ductal Adenocarcinoma Who Will Benefit from Surgical Resection.分析血浆微小RNA以鉴别能从手术切除中获益的胰腺导管腺癌患者。
Klin Onkol. 2019 Spring;32(Suppl 1):174-176.
9
Identification of key regulators of pancreatic cancer progression through multidimensional systems-level analysis.通过多维系统水平分析鉴定胰腺癌进展的关键调节因子。
Genome Med. 2016 May 3;8(1):38. doi: 10.1186/s13073-016-0282-3.
10
miR-29a Is Repressed by MYC in Pancreatic Cancer and Its Restoration Drives Tumor-Suppressive Effects via Downregulation of LOXL2.miR-29a 在胰腺癌中受 MYC 抑制,其恢复通过下调 LOXL2 发挥抑瘤作用。
Mol Cancer Res. 2020 Feb;18(2):311-323. doi: 10.1158/1541-7786.MCR-19-0594. Epub 2019 Oct 29.

引用本文的文献

1
Fibrolytic vaccination against ADAM12 reduces desmoplasia in preclinical pancreatic adenocarcinomas.针对ADAM12的纤溶酶原激活物接种可减少临床前胰腺腺癌中的促结缔组织增生反应。
EMBO Mol Med. 2024 Dec;16(12):3033-3056. doi: 10.1038/s44321-024-00157-4. Epub 2024 Oct 30.
2
Macrophages direct cancer cells through a LOXL2-mediated metastatic cascade in pancreatic ductal adenocarcinoma.巨噬细胞通过 LOXL2 介导的级联反应来指导胰腺导管腺癌中的癌细胞转移。
Gut. 2023 Feb;72(2):345-359. doi: 10.1136/gutjnl-2021-325564. Epub 2022 Apr 15.
3
Identifying Outcomes of Patients With Advanced Pancreatic Adenocarcinoma and RECIST Stable Disease Using Radiomics Analysis.

本文引用的文献

1
Specific protein 1(SP1) regulates the epithelial-mesenchymal transition via lysyl oxidase-like 2(LOXL2) in pancreatic ductal adenocarcinoma.特定蛋白 1(SP1)通过赖氨酰氧化酶样蛋白 2(LOXL2)调控胰腺导管腺癌的上皮间质转化。
Sci Rep. 2019 Apr 11;9(1):5933. doi: 10.1038/s41598-019-42501-6.
2
LIMS1 Promotes Pancreatic Cancer Cell Survival under Oxygen-Glucose Deprivation Conditions by Enhancing HIF1A Protein Translation.LIMS1通过增强HIF1A蛋白翻译促进胰腺癌细胞在氧糖剥夺条件下的存活。
Clin Cancer Res. 2019 Jul 1;25(13):4091-4103. doi: 10.1158/1078-0432.CCR-18-3533. Epub 2019 Jan 24.
3
Integrative network biology analysis identifies miR-508-3p as the determinant for the mesenchymal identity and a strong prognostic biomarker of ovarian cancer.
利用放射组学分析识别晚期胰腺导管腺癌和 RECIST 疾病稳定患者的结局。
JCO Precis Oncol. 2022 Mar;6:e2100362. doi: 10.1200/PO.21.00362.
4
MiR-29c inhibits the metastasis of oral squamous cell carcinoma and promotes its cell cycle arrest by targeting SERPINH1.微小RNA-29c通过靶向丝氨酸蛋白酶抑制剂H1抑制口腔鳞状细胞癌的转移并促进其细胞周期停滞。
Ann Transl Med. 2021 Sep;9(18):1423. doi: 10.21037/atm-21-3720.
5
Genomic Heterogeneity of Pancreatic Ductal Adenocarcinoma and Its Clinical Impact.胰腺导管腺癌的基因组异质性及其临床影响
Cancers (Basel). 2021 Sep 3;13(17):4451. doi: 10.3390/cancers13174451.
6
Heat shock protein 47 confers chemoresistance on pancreatic cancer cells by interacting with calreticulin and IRE1α.热休克蛋白 47 通过与钙网蛋白和 IRE1α 相互作用赋予胰腺癌细胞化疗耐药性。
Cancer Sci. 2021 Jul;112(7):2803-2820. doi: 10.1111/cas.14976. Epub 2021 Jun 9.
整合网络生物学分析鉴定 miR-508-3p 为决定卵巢癌间充质特征的关键因子和强有力的预后生物标志物。
Oncogene. 2019 Mar;38(13):2305-2319. doi: 10.1038/s41388-018-0577-5. Epub 2018 Nov 26.
4
ADAM12 is a circulating marker for stromal activation in pancreatic cancer and predicts response to chemotherapy.ADAM12是胰腺癌基质激活的循环标志物,并可预测化疗反应。
Oncogenesis. 2018 Nov 16;7(11):87. doi: 10.1038/s41389-018-0096-9.
5
Redox regulation in tumor cell epithelial-mesenchymal transition: molecular basis and therapeutic strategy.肿瘤细胞上皮-间充质转化中的氧化还原调控:分子基础与治疗策略。
Signal Transduct Target Ther. 2017 Aug 18;2:17036. doi: 10.1038/sigtrans.2017.36. eCollection 2017.
6
mirDIP 4.1-integrative database of human microRNA target predictions.miRDIP 数据库 4.1——人类 microRNA 靶基因预测综合数据库。
Nucleic Acids Res. 2018 Jan 4;46(D1):D360-D370. doi: 10.1093/nar/gkx1144.
7
SerpinB2 regulates stromal remodelling and local invasion in pancreatic cancer.丝氨酸蛋白酶抑制剂B2调节胰腺癌中的基质重塑和局部侵袭。
Oncogene. 2017 Jul 27;36(30):4288-4298. doi: 10.1038/onc.2017.63. Epub 2017 Mar 27.
8
Emerging Biological Principles of Metastasis.转移的新兴生物学原理
Cell. 2017 Feb 9;168(4):670-691. doi: 10.1016/j.cell.2016.11.037.
9
Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal.赖氨酸氧化酶样蛋白2(LOXL2)的选择性靶向作用可抑制肝纤维化进展并加速其逆转。
Gut. 2017 Sep;66(9):1697-1708. doi: 10.1136/gutjnl-2016-312473. Epub 2017 Jan 10.
10
Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer.结直肠癌的共识分子亚型与精准医学的演进。
Nat Rev Cancer. 2017 Feb;17(2):79-92. doi: 10.1038/nrc.2016.126. Epub 2017 Jan 4.